Author

Deborah Dillon

Observed name: D. Dillon

Institutions: Broad Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute

Observed institutions: Broad Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute

OpenAlex ID: A5126256159

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

2026 · Paolo Tarantino, Se-Eun Kim, et al. · npj Precision Oncology · 8

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression

2026 · Triet Minh Bui, Ernesto Rojas Jimenez, et al. · Cancer Cell · 2

Tumor genomics in patients younger than 40 years of age with metastatic breast cancer

2026 · Kristen D. Brantley, Ananya Kodali, et al. · npj Precision Oncology · 1

Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study

2026 · R. A. Freedman, H. Heiling, et al. · Clinical Cancer Research · 1

Tlsb-06 Multiplexed Immunostaining Identifies Epigenetic Dependency of Breast Cancer Brain Metastasis

2026 · Jun Nishida, Zheqi Li, et al. · Neuro-Oncology Advances

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype

2026 · Anlan Cao, Sophia Fuller, et al. · Breast Cancer Research

Genomic markers of resistance to first-line (1L) therapy with a CDK4/6 inhibitor (CDKi) and endocrine therapy (ET) in patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (MBC).

2026 · Albert Grinshpun, Yvonne Y. Li, et al. · Journal of Clinical Oncology

Abstract B064: KDM2-mediated epigenetic mechanism regulates brain metastasis of breast cancer

2026 · Jun Nishida, Zheqi Li, et al. · Cancer Research

Works count: 8

Citation count: 12

H-index: 2

I10-index: